IP Library Granted Patent US 7,279,150
Granted Patent B2
US 7,279,150 · App. 10/765,299 · Granted Oct 9, 2007

Chelating agents with lipophilic carriers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,279,150
App. No.
10/765,299
Granted
Oct 9, 2007
Kind
B2
Abstract

Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.

Claims (31)

1. A compound of the formula:

wherein Ch represents a chelating moiety comprising at least two nitrogens spaced by alkylene groups and to which carboxylic acid-bearing moieties are coupled;

m is 0-3;

each R 1 is independently a non-interfering substituent selected from the group consisting of halo, OR, NR 2 , SR, CN, NO 2 , SO 3 H, and R where R is alkyl or alkenyl optionally substituted by halo, or ═O, and optionally containing a heteroatom, such as O, S or N;

l is 0-2;

Z is S or O;

R 2 is H or alkyl (1-4C);

n is 1; and

each R 3 is independently an optionally substituted saturated or unsaturated hydrocarbyl group containing at least 10C, and

spacer is —CH 2 CH 2 — and/or includes a peptide, a pseudopeptide, or a polyalkylene glycol, optionally containing a cleavage site.

2. The compound of claim 1 , wherein the spacer is CH 2 CH 2 and R 2 is H.

3. The compound of claim 1 , wherein Z is S.

4. The compound of claim 1 , wherein R 2 is H.

5. The compound of claim 1 , wherein 1 is 0 and m is 1 or 0.

6. The compound of claim 1 , wherein each R 3 COO is a residue of a naturally occurring fatty acid or a mixture of said residues.

7. The compound of claim 1 , wherein R 1 is CH 3 O.

8. The compound of claim 1 , wherein the spacer is a peptide or a polyalkylene glycol.

9. The compound of claim 1 , which further comprises, associated with Ch, a paramagnetic metal ion or a radionuclide metal.

10. A composition which comprises the compound of claim 1 associated with lipophilic nanoparticles or microparticles.

11. A composition which comprises the compound of claim 9 associated with lipophilic nanoparticles or microparticles.

12. The composition of claim 10 , wherein said particles contain at least 2,000 copies of the compound of claim 1 .

13. The composition of claim 11 , wherein said particles contain at least 2,000 copies of the compound of claim 9 .

14. The composition of claim 10 , wherein the nanoparticles or microparticles further contain a targeting agent.

15. The composition of claim 11 , wherein the nanoparticles or microparticles further contain a targeting agent.

16. The composition of claim 14 , wherein said targeting agent is a receptor ligand or an antibody or fragment thereof.

17. The composition of claim 15 , wherein said targeting agent is a receptor ligand or an antibody or fragment thereof.

18. The composition of claim 10 , wherein said microparticles or nanoparticles further comprise a biologically active agent.

19. The composition of claim 11 , wherein said microparticles or nanoparticles further comprise a biologically active agent.

20. The composition of claim 10 , wherein said microparticles or nanoparticles are liposomes, oil droplets, perfluorocarbon nanoparticles, lipid-coated protein particles, or lipid-coated polysaccharides.

21. The composition of claim 11 , wherein said microparticles or nanoparticles are liposomes, oil droplets, perfluorocarbon nanoparticles, lipid-coated protein particles, or lipid-coated polysaccharides.

22. A method to obtain a magnetic resonance image or an image produced by a radionuclide which method comprises imaging a tissue which is associated with the composition of claim 11 .

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded May 3, 2010
From: PROLOG CAPITAL II, L.P.; CHARTER LIFE SCIENCES, L.P.; MEMPHIS BIOMED VENTURES II, L.P.; TRIATHLON MEDICAL VENTURES FUND, L.P.; ADVANTAGE CAPITAL COMMUNITY DEVELOPMENT FUND XV, LLC; ALAFI CAPITAL COMPANY, LLC; APJOHN VENTURES FUND, LP; VECTIS LIFE SCIENCES FUND I, L.P.; WICKLINE, SAMUEL A., M.D.; 1998 CO-INVESTING LLC; C. AGANOSTOPOULOS REVOCABLE TRUST U/A 12/21/1978
To: KEREOS, INC.
Reel/Frame 024320/0741 →
SECURITY AGREEMENT Recorded Jul 17, 2009
From: KEREOS, INC.
To: PROLOG CAPITAL II, L.P.; CHARTER LIFE SCIENCES, L.P.; MEMPHIS BIOMED VENTURES II, L.P.; TRIATHLON MEDICAL VENTURES FUND L.P.; ADVANTAGE CAPITAL COMMUNITY DEVELOPMENT FUND XV, LLC; ALAFI CAPITAL COMPANY, LLC; APJOHN VENTURES FUND, LP; VECTIS LIFE SCIENCES FUND I, L.P.; WICKLINE, SAMUEL A., M.D.; 1998 CO-INVESTING LLC; C. AGANOSTOPOULOS REVOCABLE TRUST U/A 12/21/1978
Reel/Frame 022960/0670 →